Spruce Biosciences (NASDAQ:SPRB – Get Free Report) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Spruce Biosciences to similar companies based on the strength of its earnings, dividends, risk, valuation, profitability, analyst recommendations and institutional ownership.
Analyst Recommendations
This is a breakdown of current ratings and price targets for Spruce Biosciences and its peers, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Spruce Biosciences | 1 | 0 | 11 | 0 | 2.83 |
| Spruce Biosciences Competitors | 9869 | 15283 | 45611 | 1598 | 2.54 |
Spruce Biosciences presently has a consensus target price of $158.33, indicating a potential upside of 263.77%. As a group, “Biotechnology” companies have a potential upside of 122.72%. Given Spruce Biosciences’ stronger consensus rating and higher possible upside, research analysts clearly believe Spruce Biosciences is more favorable than its peers.
Risk and Volatility
Spruce Biosciences has a beta of 3.57, suggesting that its stock price is 257% more volatile than the S&P 500. Comparatively, Spruce Biosciences’ peers have a beta of -1.84, suggesting that their average stock price is 284% less volatile than the S&P 500.
Profitability
This table compares Spruce Biosciences and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Spruce Biosciences | N/A | -118.22% | -88.36% |
| Spruce Biosciences Competitors | -12,323.33% | -195.38% | -30.39% |
Valuation and Earnings
This table compares Spruce Biosciences and its peers top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Spruce Biosciences | $4.91 million | -$38.97 million | -1.29 |
| Spruce Biosciences Competitors | $756.66 million | $13.58 million | -18.98 |
Spruce Biosciences’ peers have higher revenue and earnings than Spruce Biosciences. Spruce Biosciences is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Insider & Institutional Ownership
91.7% of Spruce Biosciences shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 4.3% of Spruce Biosciences shares are held by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Spruce Biosciences beats its peers on 8 of the 13 factors compared.
About Spruce Biosciences
Spruce Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for rare endocrine disorders. The company’s research is centered on conditions in which abnormal hormone production or regulation creates significant health risks and limited treatment options. Its lead investigational product is tildacerfont, an oral, selective corticotropin-releasing factor type 1 receptor antagonist. Spruce has studied tildacerfont as a potential treatment for congenital adrenal hyperplasia, a rare genetic disorder affecting the adrenal glands, and has evaluated its ability to reduce hormone imbalances associated with the disease.
Receive News & Ratings for Spruce Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spruce Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
